Global Mammalian Polyclonal IgG Antibody Market by Product (Metabolic, Cardiac), by Type (Rabbit, Mouse) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

In 2017, the global mammalian polyclonal IgG market was worth USD 816.5 millions. It is expected to grow at a 5.1% CAGR during the forecast period. Market growth is driven by the advantages of polyclonal IgG antibodies over other types, rising R&D investments and increasing adoption of new diagnostic procedures.

Polyclonal antibodies are often the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. These antibodies can be made quickly and easily by skilled professionals. Large quantities can also be produced according to client needs.

The rise in investment by pharmaceutical and biotechnology companies has resulted in technological advances in antibody production. These technological advances have increased product demand and thereby boosted the mammalian polyclonal IgG market. Biopharma companies have made significant investments in recent years to develop new, more efficient antibodies as well as for quality control purposes.

The top 10 biotech companies invested USD 8.2 billion in R&D in 2010, and USD 10.2 billion in 2016, a 13% increase. In diagnosing chronic diseases such as diabetes, cancer, and autoimmune diseases, mammalian polyclonal IgG antibody are increasingly being used.

Global market is also being boosted by the increasing use of biomarkers to provide accurate and quick diagnosis. Clinicians are increasingly using CD20 biomarkers to diagnose B-cell lymphoma or leukemia. This has led to an increase of demand for these products.

Product Insights

The mammalian IgG monoclonal antibody market can be segmented by product type into metabolic, cardiac, renal and other biomarkers. The cardiac biomarkers market is growing due to the rising prevalence of Cardiovascular Diseases (CVDs), unhealthy eating habits, lack of exercise, and sedentary lifestyle. A wide variety of diseases can be tested using metabolic biomarkers. This segment is expected to grow at a highest CAGR of 5.5% over the forecast period.

It is expected that diabetes will grow as more people use metabolic biomarkers to diagnose it. According to the International Diabetes Federation, more than 425 million people worldwide were affected by diabetes in 2017. Type II diabetes, which is the most prevalent type of diabetes, affects 90% of those affected. The segment's growth is expected to be fueled by the increasing incidence of cancer worldwide. The study also includes biomarkers that can be used to detect cancer and autoimmune diseases.

Type Insights

The market can be divided into several segments based on the animal host. Due to the predominant use of mice for polyclonal antibody manufacturing, the mouse segment will likely show the highest CAGR. The antibody and antigen structural forms of mice and humans are very similar. This is why it is being used more in research. The mouse segment will generate significant revenue by 2025.

Rabbit antibodies have a high level of specificity and a stronger immune response to small epitopes. This allows for increased disease recognition. Large variety of high-affinity antibodies produced by rabbits aids in finding immunoglobulins that have a wide range of applications, such as immunohistochemistry, ELISA, Western Blotting, immunocytochemistry, and others. This will have a positive effect on segment growth.

Antibodies are usually obtained from large animals such as horses when large quantities of antisera are required. Horses can also be used to produce antibodies for many diseases, including asthma, tuberculosis and Crohn's disease. The treatment of diphtheria, snake bites, tetanus and other diseases has been done with horse antisera. Because of their similarity to humans, mice are very useful in research on complex diseases. Research on atherosclerosis and hypertension are mostly conducted with mice as hosts. This segment is expected to grow in market share due to all of these factors.

Application Insights

On the basis of application, the market is segmented into ELISA, immunoturbidometry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting. Due to its specificity and sensitivity, western blotting was the most popular method of revenue generation in 2017. Western Blotting allows for disease detection using few antibodies and significantly reduces laboratory costs. Another key reason for the increased demand is its protein specificity.

The ELISA segment will see the greatest CAGR of 5.8% in the coming years, due to its use in antibody-related tests. Because it accurately diagnoses diseases such as Lyme disease, AIDS, pernicious and viral infections, it is the most commonly used test. The immunohistochemistry, used in tumor detection, is expected to account for a significant market share in the near future.

This is due to the higher specificity of the equipment, which helps in identifying structural differences often seen in tumor cells. The segment will grow due to increased adoption and improvements in equipment.

End Use Insights

The market can be divided by end use into hospitals, diagnostic centres, academic and research centers. The growth of diagnostic centers is expected to be influenced by rising disease prevalence and increased use of biomarkers in testing and diagnosis. The largest market share was due to the high use of polyclonal antibody for disease diagnosis. According to the World Health Organization, the number of tropical diseases such as yellow fever, chikungunya and chikungunya has increased dramatically, which has fueled the demand for polyclonal antibody.

The segment of diagnostic centers is expected to grow in the future. Research and academic centers saw significant revenue growth in 2017, due to the increased research on personalized medicine and improved drug efficacy. Due to the large number of patients and diagnostic tests performed in hospitals, they held a significant market share. This segment has seen a rise in the number of hospitals around the world. This segment will continue to grow due to the increasing prevalence of chronic illnesses and the need for hospitals that can detect antigens in patient samples.

Regional Insights

North America dominated the market in 2017, thanks to its well-equipped research facilities, and the leading companies that produce antibodies in the region. Regional growth will be driven by the adoption of advanced technologies as well as a focus on clinical research. The U.S. has favorable reimbursement policies that have encouraged the use of polyclonal antibodies techniques.

The dominance of the region market has been made possible by the presence of government agencies such as CDC. The key factors driving the growth are increasing awareness and increased R&D activities. The market will be boosted by collaboration programs between the U.S., China, and biomedical research. Research funding will also increase during the study period.

APAC is expected to experience the greatest growth due to the rising disposable income and the increasing prevalence of diabetes and cancer. The market will be boosted by the increased focus of major manufacturers on expanding their presence in emerging APAC countries.

The Japanese government, for example, provides funding to Okinawa Health Biotechnology Research and Development Center. This center provides research facilities free of charge to biotechnology companies. Hence, APAC's regional market growth is driven by rising investment from pharmaceutical and biopharmaceutical firms as well as high disease incidences.

Mammalian Polyclonal Antibody IgG Market Share Insights

There are many local and global companies that make up the market. Abcam PLC, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Merck KGaA, Cell Signaling Technology, Inc., and F. Hoffman-La Roche are some of the major companies. These companies have strong geographical presences in terms of their distribution networks and operating facilities. Abcam PLC, for example, is present in more than 130 countries.

To gain an edge over competitors, these organizations have implemented various business strategies such as M&A and strategic deals. Abcam, for example, signed an exclusive license agreement in January 2018 with Roche AG. This will allow Abcam to access the product portfolio from Spring Bioscience Corporation for research purposes. This portfolio includes over 243 monoclonal recombinant rabbit antibodies.

Most market players also pursue regional expansion. Abcam, for example, announced in November 2015 that it would be launching a direct service to Singapore in order to increase collaborations with companies and research institutes in the Asia Pacific region.

Mammalian Polyclonal Antibody Market Report Scope

The Report Covers Certain Segments

This report forecasts volume growth and revenue at the global, regional and country level. It also provides analysis of industry trends for each sub-segment from 2014 through 2025. Grand View Research has divided the global mammalian polyclonal IgG antibodies market report by type, product, app, end use, region, and country.

• Type Outlook (Revenue USD Million, 2014-2025)

  • Goat

  • Rabbit

  • Horse

  • Mouse

  • Other

• Product Outlook (Revenue USD Million, 2014-2025)

  • Cardiac Markers

  • Metabolic Markers

  • Renal Markers

  • Other

• App Outlook (Revenue USD Million, 2014-2025)

  • ELISA

  • Immunoturbidometry

  • Immunoelectrophoresis

  • Antibody Identification

  • Immunohistochemistry

  • Immunocytochemistry

  • Western Blotting

• End Use Outlook (Revenue USD Million, 2014-2025)

  • Hospitals

  • Diagnostic Centers

  • Research and Academic Institutes

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

    • Saudi Arabia

These are the most frequently asked questions about this report

b. The global mammalian polyclonal IgG market was valued at USD 897.2 millions in 2019, and is forecast to grow to USD 941.5million in 2020.

b. Global mammalian polyclonal IgG markets are expected to grow at a compound annual rate of 5.08% between 2019 and 2025, to reach USD1.2 billion by 2025.

b. North America was the dominant market for mammalian polyclonal IgG in 2019, with a 35.1% share. This is due to the existence of highly-equipped research facilities in the region and the production of antibodies by leading companies. Regional growth will be driven by the rapid adoption of advanced technologies as well as a focus on clinical research.

b. Among others, there are Abcam PLC, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Merck KGaA, Cell Signaling Technology, Inc., and F. Hoffman-La Roche.

b. The market growth is being driven by the increase in investments made by pharmaceutical and biotech companies, which has led to significant demand for these antibodies.

Up Market Research published a new report titled “Mammalian Polyclonal IgG Antibody Market research report which is segmented by Product (Metabolic, Cardiac), by Type (Rabbit, Mouse), By Players/Companies Inc; and F Hoffman-La Roche among others, Abcam PLC; Bio-Rad Laboratories; Thermo Fisher Scientific, Inc; Merck KGaA; Cell Signaling Technology”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Mammalian Polyclonal IgG Antibody Market Report Segments:

The market is segmented by Product (Metabolic, Cardiac), by Type (Rabbit, Mouse).

Mammalian Polyclonal IgG Antibody Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Mammalian Polyclonal IgG Antibody Market

Overview of the regional outlook of the Mammalian Polyclonal IgG Antibody Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Mammalian Polyclonal IgG Antibody Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Mammalian Polyclonal IgG Antibody Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Metabolic

                2. Cardiac

                1. Rabbit

                2. Mouse

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Mammalian Polyclonal IgG Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Mammalian Polyclonal IgG Antibody Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.